, Volume 64, Issue 3, pp 123-127

Low-dose interferon-alpha in stage-I multiple myeloma and in IgM monoclonal gammopathy

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Interferon (IFN)-a can induce objective responses in advanced-stage multiple myeloma (MM) and can delay disease progression in patients responsive to chemotherapy. We studied the effects of low-dose (3 MU daily) human recombinant IFN-α 2b for 6–12 months in 29 consecutive cases of previously untreated, stablephase, early stage, monoclonal gammopathy (MG) (23 cases of stage I MM and six cases of IgM MG). In 25/29 patients, the disease remained stable throughout the study period. A major objective response was observed in one of five cases of IgA MG. Normal Ig levels increased in all five cases of IgA MG. A significant disease progression occurred in 2/29 cases during the 1-year study period. These data showed that the objective response rate of early-stage MG to low-dose IFN was low and suggested that further investigation should focus on IgA MG.

Writing committee: R. Fanin, D. Russo, F. Patriarca, C. Gallizia, and M. Baccarani.Pathology committee: S. Pileri, E. Sabattini (Bologna).Active members: G. Fasola, L. Virgolini, D. Damiani, M. Michieli, A. Geromin (Udine); P. Cristina, A. Polacco, E. Radin (Mestre); M. Buttò, E. Rorai, C. Mazzaro (Pordenone); M. N. De Savorgnani, D. Magris (Trieste); A. Guaran, F. Montanar (Palmanova); Q. Messina, A. Cellini (Sacile); F. Saladin, M. Ferrarese (Treviso); O. Fantin, R. Nimis (Latisana); M. A. Monco, G. Conte (Treviso); G. Pozzato (Trieste); E. Tomat, P. Naliato (Udine)
Work supported by AIRC (Milano), bySezione Friulana della Lega Italiana per la Lotta contro i Tumori, and by the University of Udine, grants 60%. F. Patriarca is an AMS/FVG fellow